Union Ministry of Health Proposes Amendments to Schedule M to Align Grade A Microbial Monitoring Requirements with WHO Guidelines

1. At a Glance

• The Union Ministry of Health and Family Welfare (MoHFW) has published a draft amendment to Schedule M of the Drugs Rules, 1945. It would bring the microbial contamination limits for Grade A clean areas into line with WHO TRS No. 1044, Annex 2 [1].
• Schedule M sets Good Manufacturing Practices (GMP) for pharmaceutical manufacturing in India. The amendment covers sterile pharmaceutical products, where contamination directly affects patient safety [1].
• The main change: any microbial growth in a Grade A area becomes a trigger for investigation. The test is no longer whether a numeric limit was crossed [1]. This matches WHO's "No growth" limit for Grade A [5].
• Why it matters: India's reputation as a drug exporter, drug-quality scandals, and global harmonisation of rules. Relevant to GS-II (Health) and GS-III (Industry).

2. Why in the News

• G.S.R. No. 953(E), dated 28 October 2026: MoHFW notified a draft amendment that revises the Grade A microbial contamination limits in the Revised Schedule M [1].
• Objections and suggestions have been invited. They go to the Under Secretary (Drugs Regulation), MoHFW, so the amendment is still a draft [1].

3. Background & Evolution

• 1945: The Drugs Rules framed. Schedule M is the part that prescribes GMP and the requirements for premises, plant and equipment [1][2].
• 2011: WHO publishes GMP for sterile pharmaceutical products as TRS No. 961, Annex 6 [4].
• 2022: WHO publishes the revised text as TRS No. 1044, Annex 2 (WHO page dated 31 October 2022). It was prepared with the European Union and PIC/S [4].
• 28 December 2023: Schedule M revised through G.S.R. 922(E). It added a Pharmaceutical Quality System, Quality Risk Management, and qualification and validation, aligned with WHO standards [2].
• 2024: Large manufacturers (turnover above ₹250 crore) had to comply by June 2024 [2]. The CDSCO and State Drugs Controllers carried out risk-based inspections of 400 premises, including MSMEs [6].
• February 2025: For small and medium manufacturers (turnover ₹250 crore or less), the compliance deadline was extended, with conditions, to 31 December 2025 [3]. Some PIB releases say 1 January 2026 instead [2].
• 28 October 2026: G.S.R. 953(E) proposed to align the Grade A microbial norms with WHO [1].

4. Core Static Facts

Item	Fact
Rules being amended	Drugs Rules, 1945, Schedule M (Revised Schedule M) [1]
Ministry	MoHFW [1]
Draft notification	G.S.R. 953(E), 28 Oct 2026 (draft; public comments invited) [1]
Earlier revision	G.S.R. 922(E), 28 Dec 2023 [2]
International benchmark	WHO TRS No. 1044, Annex 2: GMP for Sterile Pharmaceutical Products [1][4]
What TRS 1044 Annex 2 replaced	TRS 961, Annex 6 (2011) [4]
Co-developed with	EU and PIC/S [4]
WHO Grade A microbial limit	"No growth", checked in both at-rest and operational states during qualification [5]
Grade A definition	The critical zone where exposed products, containers and sterilised components are handled [1]
MSME threshold under revised Schedule M	Turnover ≤ ₹250 crore [2][3]

• Key terms
• GMP: quality standards for how medicines are made [1].
• Clean-area grades (A–D): Grade A is the most critical. Under WHO guidance, aseptic filling and connections take place in Grade A with a Grade B or C background, depending on the operation [5].
• Investigation trigger: any growth detected in Grade A must be investigated for its root cause [1].

5. Multi-Dimensional Analysis

Economic

• Aligning with WHO GMP helps Indian sterile injectables meet the WHO Prequalification standard. WHO PQ inspections use TRS 1044 Annex 2 as their benchmark [8].
• MSMEs face higher compliance costs: cleanroom upgrades, environmental monitoring, investigation systems. The repeated deadline extensions point to limited capacity [3].

Social / Public Health

• Contamination of sterile products (injectables, ophthalmics) can cause sepsis and deaths. A zero-growth investigation rule reduces risk for patients.
• The amendment fits a wider drug-quality drive after the cough-syrup episodes. The Union Health Secretary chaired a review with States/UTs on cough-syrup quality [7].

Legal / Regulatory

• The change is made by delegated legislation: a G.S.R. notification issued as a draft with a public consultation window before final notification [1].
• Harmonising with WHO TRS 1044 also brings India closer to EU and PIC/S norms, since WHO wrote the text with them [4].

Scientific / Technological

• The approach shifts from a numeric limit-compliance model to risk-based contamination control. This is consistent with Quality Risk Management in the 2023 Revised Schedule M [2].
• Grade A qualification needs microbial monitoring in both at-rest and operational states [5].

Governance / Administrative

• Enforcement is split between the CDSCO and State Drugs Controllers. Joint risk-based inspections show how the two levels work together [6].
• Weak state-level inspection capacity is a bottleneck for consistent enforcement.

6. Recent Developments (last 12–18 months)

• Feb 2025: MSME compliance deadline for revised Schedule M extended, with conditions, to 31 Dec 2025 [3].
• 2025: The Centre reviewed cough-syrup quality with States/UTs [7].
• 28 Oct 2026: Draft G.S.R. 953(E) released to align Grade A microbial limits with WHO TRS 1044 Annex 2; comments invited [1].

7. Prelims Hooks

• Schedule M of the Drugs Rules, 1945 prescribes GMP for pharmaceutical products [1][2].
• Revised Schedule M was notified through G.S.R. 922(E), 28 December 2023 [2].
• The draft amendment G.S.R. 953(E) is dated 28 October 2026 [1].
• The benchmark is WHO TRS No. 1044, Annex 2, GMP for Sterile Pharmaceutical Products [1].
• TRS 1044 Annex 2 replaced TRS 961, Annex 6 (2011) [4].
• TRS 1044 Annex 2 was drafted with the European Union and PIC/S [4].
• WHO's Grade A microbial limit is "No growth" [5].
• Under the proposal, any microbial growth in Grade A triggers an investigation [1].
• Grade A is where exposed products, containers and sterilised components are handled [1].
• Comments go to the Under Secretary (Drugs Regulation), MoHFW [1].
• Under revised Schedule M, large firms are those with turnover > ₹250 crore; MSMEs got extended deadlines [2][3].
• Ministry: MoHFW, not the Department of Pharmaceuticals (which sits under the Ministry of Chemicals & Fertilizers) [1].

8. The Recent Deaths Came From Syrups, Not From Sterile Rooms

• The child deaths that shook India's drug image were caused by poison in syrups, not by germs
• In October 2025, WHO issued Medical Product Alert N°5/2025 on three Indian oral liquid medicines, including COLDRIF [9].
• CDSCO found diethylene glycol (DEG, an industrial chemical that is toxic and can kill when swallowed) in them. WHO linked them to clusters of illness and child deaths [9].

• The 2022 Gambia case was the same kind of failure: four Maiden Pharmaceuticals (Haryana) syrups contained unsafe amounts of DEG and ethylene glycol [10].

• Why this matters for G.S.R. 953(E)

• The draft only changes microbial (germ) limits in Grade A rooms. Grade A is used for sterile products such as injections [1].
• A cough syrup is not made in a Grade A room. A better Grade A rule cannot stop a poisoned solvent from getting into a syrup.

• So the note's link to the 'cough-syrup crackdown' is a link of timing and mood, not a cause-and-effect link. Do not write in Mains that this amendment 'responds to' the cough-syrup deaths.

• What the amendment does fix

• It closes a different gap: India's sterile-product rule now matches the WHO text that WHO Prequalification inspectors use [4][8].
• That helps Indian injectables get past global buyers and inspectors. It is an export-credibility reform more than a reaction to a domestic disaster.

9. A 'Zero Growth' Rule Is Only As Strong As the Investigation Behind It

• The rule changes what a firm must do after a test, not how often anyone checks the firm
• Under the draft, any growth in Grade A must lead to a root-cause investigation, meaning the firm must find out where the germs came from [1].
• Under WHO GMP, the manufacturer runs this monitoring itself, as part of its own contamination control system [5].

• So the first person to see a positive result, and the first person to write the investigation report, is the company.

• A strict rule can create a reason to hide results

• Under a numeric limit, a small count could be passed off as 'within limit'. Under 'no growth', every positive plate creates paperwork, delays and possible batch rejection.

• Unless inspectors check the raw monitoring records, a firm under cost pressure has a reason to under-report rather than investigate.

• Inspections are still driven by past failures

• CDSCO and State Drugs Controllers choose firms for risk-based inspection using criteria such as the number of drugs declared Not of Standard Quality (NSQ, a sample that failed a quality test), complaints and how critical the product is [6].

• This mostly finds firms after something has already gone wrong. A sterile unit with a weak investigation system but no failed samples yet may not be picked.

• The weak link is the inspector, not the rule

• Licensing and much of the enforcement sit with State Drugs Controllers [6]. A 'no growth' rule needs inspectors trained to judge whether an investigation was honest and complete. That is harder than checking whether a number was crossed.

10. Who Pays for Cleaner Rooms: The MSME Money Gap

• The government's help scheme pays only after the firm has already spent the money
• Under RPTUAS (Revamped Pharmaceuticals Technology Upgradation Assistance Scheme, run by the Department of Pharmaceuticals), support is a reimbursement, not an upfront loan subsidy [12].
• Money is released only after a drug regulator certifies that the unit complies with revised Schedule M [11].

• So a cash-poor small firm must first find the full money to upgrade, pass inspection, and only then get part of it back.

• The subsidy covers a small share of the cost

• The incentive is 10% to 20% of eligible investment, depending on turnover, with a cap of ₹2 crore [11].

• The firm still pays 80–90% itself. Upgrading a sterile cleanroom and its monitoring system is among the costliest parts of GMP.

• Money reaches firms slowly

• By early 2026, 255 companies had sanctions worth ₹248.20 crore. Only ₹18.25 crore had been approved for payment, to 19 companies [11].

• The outlay was ₹300.10 crore for 2024-25 to 2025-26 [11]. Most of the sanctioned money had not yet reached firms when the general MSME deadline arrived [3].

• The fair objection, and its answer

• Objection: a stricter Grade A rule, coming soon after the main Schedule M deadline, could push small sterile makers out and raise the price of cheap injectables.
• The objection is right about cost and timing. That is why the repeated deadline extensions happened [3].
• But it is weak on the standard itself. Grade A covers the point where an open sterile product meets the air [1]. A germ there goes straight into a patient's blood or eye. A lower standard for small firms would mean a lower standard for poorer patients who buy their products. The answer is better financing, not a softer rule.

11. What Should Happen Before the Draft Becomes Final

• Department of Pharmaceuticals: release RPTUAS money in stages for sterile units
• Today the money comes only after certification [11]. Paying part of it when a sanctioned upgrade reaches an agreed stage would help firms that cannot raise the full cost first.

• The scheme already limits the incentive by turnover and caps it [11], so staged release would not raise the government's total cost.

• CDSCO: put sterile units on the risk-based inspection list by default

• 'Criticality of the product' is already one of CDSCO's selection criteria [6].

• Treating every Grade A aseptic operation as high-risk would let inspections check investigation records before a failure, not after.

• MoHFW and CDSCO: inspect against the same text WHO uses

• WHO Prequalification inspectors already check sterile sites against TRS 1044 Annex 2 [8].

• If Indian inspectors use the same text and the same way of judging investigations, Indian approval will mean the same as WHO approval. That is the real export gain [4].

• MoHFW: deal with the syrup problem through its own rules

• The DEG deaths need testing of raw materials and solvents in oral liquids [9][10], not cleanroom rules.

• Presenting G.S.R. 953(E) as part of the cough-syrup response may give a false sense that that gap is closed.

• Longer term: work towards PIC/S membership

• PIC/S (the Pharmaceutical Inspection Co-operation Scheme, a group of national drug inspectorates) co-wrote the WHO sterile text [4].
• Aligning the paper rule is the first step. Membership would require India to show that its inspections, not just its rules, meet the same standard.

12. Anchors for Answers

• Data: RPTUAS — 255 companies sanctioned ₹248.20 crore, but only ₹18.25 crore approved for payment to 19 companies by early 2026; incentive 10–20% of investment, capped at ₹2 crore [11]
• Data: WHO Medical Product Alert N°5/2025 (13 Oct 2025) — DEG found in three Indian oral liquid medicines, including COLDRIF, linked to child deaths [9]; earlier alert N°6/2022 — four Maiden Pharmaceuticals syrups linked to child deaths in The Gambia [10]
• Law/Case: Drugs Rules, 1945, Schedule M — revised by G.S.R. 922(E) (2023); Grade A limits amended by draft G.S.R. 953(E) (2026) [1][2]
• Comparison: WHO Prequalification inspects sterile sites against TRS 1044 Annex 2, co-written with the EU and PIC/S. India's draft adopts the same 'no growth' Grade A standard [4][5][8]
• Scheme: RPTUAS (Department of Pharmaceuticals) — reimbursement for units with turnover under ₹500 crore to upgrade to revised Schedule M; paid only after the regulator certifies compliance [11][12]

13. Mains Relevance

• GS-II: Issues relating to development and management of the health sector; government policies and interventions.
• GS-III: Industrial policy and changes in industrial policy; effects on industrial growth (pharma, MSMEs).
• Question stems 1. "Harmonising Indian GMP norms with WHO standards is essential to sustain India's position as the 'pharmacy of the world'. Examine with reference to recent amendments to Schedule M." (GS-III, 15 marks) 2. "Repeated drug-contamination incidents expose gaps in India's drug-regulatory framework. Discuss the role of Revised Schedule M and the challenges in enforcing it, especially for MSMEs." (GS-II, 15 marks) 3. "Moving from limit-based compliance to risk-based quality systems: assess this shift in pharmaceutical regulation." (GS-II/III, 10 marks)

14. Related Topics to Study Next

• Drugs and Cosmetics Act, 1940: the parent statute under which the Drugs Rules are framed. Not covered in the sources retrieved here; verify separately.
• CDSCO and the DCGI: central regulator that runs joint inspections with the States [6].
• WHO Prequalification Programme: uses TRS 1044 as its inspection benchmark [8].
• PIC/S: co-developer of the sterile GMP text; India's possible membership is an exam angle [4].
• Cough-syrup contamination episodes (DEG/EG): the trigger for the wider quality crackdown [7].
• Revamped Pharmaceuticals Technology Upgradation Assistance Scheme (RPTUAS): Department of Pharmaceuticals support to help MSMEs meet Schedule M (from the PIB search results).
• Federal split in drug regulation: licensing by the States, standards set by the Centre.

15. NCERT Concepts to Revise

• Delegated legislation (Polity): The amendment is a draft G.S.R. notification: the executive changes Drugs Rules under powers given by an Act, with public comments.
• Micro, small and medium enterprises (Economy): Small drugmakers face the highest cost of cleanroom upgrades, which is why compliance deadlines were repeatedly extended.
• Subsidy (Economy): The RPTUAS scheme reimburses 10–20% of upgrade costs, but pays only after compliance is certified, so cash-poor firms struggle.
• Export (Economy): Aligning with WHO standards helps Indian injectables pass global inspections and protects India's standing as a drug exporter.
• Industrial policy (Economy): Schedule M changes, deadlines and the upgrade scheme are government tools shaping how the pharmaceutical industry grows and is regulated.

16. Common Errors / Trap Areas

• Draft vs final: G.S.R. 953(E) is a proposal open to comments, not a final rule [1].
• Mixing up the notifications: 922(E) (2023) revised Schedule M as a whole. 953(E) (2026) only targets Grade A microbial limits [1][2].
• Wrong WHO document: the current sterile GMP text is TRS 1044 Annex 2. TRS 961 Annex 6 (2011) is the superseded version [4].
• Wrong ministry: MoHFW amends the Drugs Rules, not the Department of Pharmaceuticals [1].
• MSME deadline: sources give either 31 Dec 2025 or 1 Jan 2026 [2][3]. Also, the exact numeric Grade A limit in the current Schedule M could not be confirmed from the allowed sources, so don't memorise a specific CFU figure.